Envista Holdings Corp (NYSE: NVST) is a Healthcare company in the Medical - Instruments & Supplies industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 39.58 | EPS (ttm) | 0.59 | Insider Own | 1.78% | Shs Outstand | 162.73M | Perf Week | -8.61% |
| Market Cap | 3.80B | Forward P/E | 13.99 | EPS next Y | 1.67 | Insider Trans | -0.28% | Shs Float | 162.02M | Perf Month | -15.34% |
| Enterprise Value | 3.80B | PEG | 0.44 | EPS next Q | 0.36 | Inst Own | - | Short Float | 7.03% | Perf Quarter | -9.88% |
| Income | 95.37M | P/S | 1.33 | EPS this Y | 164.40% | Inst Trans | - | Short Ratio | 4.20 | Perf Half Y | -7.56% |
| Sales | 2.86B | P/B | - | EPS next Y | 8.87% | ROA | 1697307.53% | Short Interest | 11.38M | Perf YTD | 7.55% |
| Book/sh | - | P/C | 12.63 | EPS next 5Y | 8.89% | ROE | 4.10% | 52W High | 30.42 -23.24% | Perf Year | 11.30% |
| Cash/sh | - | P/FCF | 16.36 | EPS past 3/5Y | -40.66% 1.49% | ROIC | 2381972.73% | 52W Low | 18.77 24.40% | Perf 3Y | -20.66% |
| Dividend Est. | - | EV/EBITDA | 10.82 | Sales past 3/5Y | 1.92% 7.11% | Gross Margin | 55.50% | Volatility | 3.94% 3.07% | Perf 5Y | -45.75% |
| Dividend TTM | - | EV/Sales | 1.33 | EPS Y/Y TTM | 108.92% | Oper. Margin | 9.92% | ATR (14) | 0.88 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.06 | Sales Y/Y TTM | 13.82% | Profit Margin | 3.33% | RSI (14) | 25.95 | Recom | 2.63 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.43 | EPS Q/Q | 57.69% | SMA20 | -11.49% | Beta | 0.88 | Target Price | 29.22 |
| Payout | 0.00% | Debt/Eq | 0.52 | Sales Q/Q | 7.18% | SMA50 | -13.31% | Rel Volume | 2.02 | Prev Close | 23.69 |
| Employees | 12,000 | LT Debt/Eq | 0.50 | Earnings | Nov 04 | SMA200 | -8.53% | Avg Volume | 2.78M | Price | 23.35 |
| IPO Date | Sep 18, 2019 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 22.30% 2.01% | Net Debt/EBITDA | 0.00 | Volume | 5,636,364 | Change | -1.44% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-18-26 | Reiterated | UBS | Neutral | $25 → $27 |
| Sep-03-26 | Reiterated | Deutsche Bank | $32 | |
| Sep-03-26 | Upgrade | JP Morgan | Neutral → Overweight | |
| Aug-06-26 | Reiterated | Morgan Stanley | Equal Weight | $21 → $23 |
| Aug-06-26 | Reiterated | Robert W. Baird | $31 → $34 | |
| Aug-06-26 | Reiterated | Mizuho Securities | Neutral | $27 → $29 |
| Jul-29-26 | Reiterated | Piper Sandler | Neutral | $25 → $26 |
| Jul-08-26 | Initiated | BMO Capital | Market Perform | $27 |
| Jun-11-26 | Reiterated | Barclays | Overweight | $24 → $32 |
| May-07-26 | Reiterated | Robert W. Baird | $30 → $31 |
Envista Holdings Corporation is an enterprise dedicated to the development and distribution of a comprehensive range of dental solutions. These offerings are crucial for the identification, therapeutic intervention, and preventative care of diverse oral health issues, specifically addressing the teeth, gingiva (gums), and their supporting bone structures. The company's principal location is in Brea, California, and it maintains a workforce comprising 12,800 full-time personnel. The firm organizes its business activities into two main divisions: "Specialty Products & Technologies" and "Equipment & Consumables." The Specialty Products & Technologies division concentrates on the creation, fabrication, and promotion of sophisticated dental implant systems, advanced prosthetic devices, and their associated digital treatment software and technological advancements. This segment also provides orthodontic remedies, including bracket systems, clear aligners, and various items for dental laboratories. Conversely, the Equipment & Consumables division is responsible for conceptualizing, producing, and bringing to market a wide array of dental apparatus and vital supplies intended for professional dental clinics. This extensive catalog includes digital imaging instruments, specialized software, and visual or magnification systems; patient treatment units and other essential fixtures for dental practices; complete endodontic kits along with their complementary consumable items; materials and tools for restorative dentistry; rotary cutting tools (burs); impression-making compounds; adhesive agents and dental cements; and products designed for infection control.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2,858 | 2,720 | 2,511 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 1,272 | 1,223 | 1,119 | — | — | — | — | — | — | |
| Gross Profit | 1,585 | 1,496 | 1,392 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 1,181 | 1,157 | 1,136 | — | — | — | — | — | — | |
| Research and Development | 120 | 114 | 99 | — | — | — | — | — | — | |
| Other Operating Expense | 1 | 0 | 1,195 | — | — | — | — | — | — | |
| Operating Income | 284 | 226 | -1,038 | — | — | — | — | — | — | |
| Interest Expense | 21 | 37 | 46 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -29 | -12 | 0 | — | — | — | — | — | — | |
| Net Income Before Taxes | 234 | 177 | -1,085 | — | — | — | — | — | — | |
| Income Taxes | 140 | 130 | 34 | — | — | — | — | — | — | |
| Consolidated Net Income | 96 | 47 | -1,119 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 96 | 47 | -1,119 | — | — | — | — | — | — | |
| Net Income | 96 | 47 | -1,119 | — | — | — | — | — | — | |
| EPS (Recurring) | 0.59 | 0.28 | -6.50 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.59 | 0.28 | -6.50 | — | — | — | — | — | — | |
| EPS (Diluted) | 0.58 | 0.28 | -6.50 | — | — | — | — | — | — | |
| EBITDA | 351 | 330 | 280 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 40.26 | 77.54 | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 1.32 | 1.34 | 1.32 | — | — | — | — | — | — | |
| Gross Margin | 55.46 | 55.00 | 55.44 | — | — | — | — | — | — | |
| Operating Margin | 9.94 | 8.31 | -41.34 | — | — | — | — | — | — | |
| Net Margin | 3.36 | 1.73 | -44.56 | — | — | — | — | — | — | |
| Shares Outstanding | 162 | 168 | 172 | — | — | — | — | — | — | |
| Market Capitalization | 3,783 | 3,647 | 3,318 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Reis Mischa | SVP, Strategy & Bus. Dev. | Aug 20 '26 | Sale | 27.50 | 8,000 | 220,000 | 27,321 | Aug 24 |
| Reis Mischa | SVP, Strategy & Bus. Dev. | Feb 10 '26 | Option Exercise | 17.25 | 9,675 | 166,916 | 38,016 | Feb 11 |
| Reis Mischa | SVP, Strategy & Bus. Dev. | Feb 10 '26 | Sale | 30.00 | 5,634 | 169,020 | 32,382 | Feb 11 |
| Reis Mischa | SVP, Strategy & Bus. Dev. | Aug 25 '25 | Sale | 21.60 | 15,000 | 324,000 | 32,382 | Aug 27 |
| Keel Paul A | Chief Executive Officer | Aug 13 '24 | Buy | 16.87 | 30,000 | 506,100 | 402,605 | Aug 14 |
| Hammes Eric D. | Chief Financial Officer | Aug 12 '24 | Buy | 16.33 | 24,532 | 400,608 | 24,532 | Aug 13 |
| Conley Eric | SVP, Orthodontics | Nov 16 '23 | Buy | 22.89 | 2,185 | 50,015 | 47,376 | Nov 20 |
| Nance Mark E | General Counsel | Nov 08 '23 | Buy | 21.75 | 5,000 | 108,750 | 39,042 | Nov 09 |
| Aghdaei Amir | Chief Executive Officer | Nov 06 '23 | Buy | 21.53 | 10,000 | 215,254 | 295,362 | Nov 07 |
| Keller Stephen | Principal Financial Officer | Nov 06 '23 | Buy | 21.53 | 2,000 | 43,060 | 13,070 | Nov 07 |
| Yu Howard H | Chief Financial Officer | Feb 28 '23 | Sale | 37.90 | 10,016 | 379,606 | 45,865 | Mar 01 |
| Yu Howard H | Chief Financial Officer | Nov 17 '22 | Sale | 36.55 | 657 | 24,013 | 51,106 | Nov 21 |
| Yu Howard H | Chief Financial Officer | Apr 18 '22 | Sale | 45.73 | 5,341 | 244,244 | 52,411 | Apr 20 |
| Aghdaei Amir | Chief Executive Officer | Mar 29 '22 | Sale | 51.50 | 3,801 | 195,752 | 364,779 | Mar 31 |
| Yu Howard H | Chief Financial Officer | Mar 21 '22 | Option Exercise | 21.76 | 4,786 | 104,144 | 59,682 | Mar 22 |